Kolon TissueGene (950160) Q4 2025 earnings summary

Executive summary

• Focus on cell and gene therapy development, with TG-C as the lead product for osteoarthritis, currently in phase 3 clinical trials in the US.

• Diversified into integrated distribution (health & beauty, lifestyle products) alongside core biotech operations.

• Significant R&D investment, with a robust pipeline targeting knee, hip, and spinal disc degenerative diseases.

• Multiple capital raises and convertible bond issuances to fund ongoing clinical trials and operations.

Financial highlights

• 2025 revenue: $3.63M, down 2.5% year-over-year; operating loss: $15.7M, slightly improved from prior year.

• Net loss for 2025: $135.4M, significantly higher than 2024 due to derivative valuation losses on convertible bonds.

• Cash and cash equivalents at year-end: $47.2M, up from $0.5M in 2024, reflecting new equity and bond funding.

• R&D expenses (capitalized and expensed): $87.2M in 2025, representing 2,404% of sales.

• Total assets: $295.5M; total liabilities: $250.8M; equity: $44.7M at year-end 2025.

Outlook and guidance

• Completion of phase 3 pivotal studies for TG-C in knee osteoarthritis, with 1,066 patients enrolled and dosing finished in July 2024.

• Two-year follow-up for all patients underway; BLA submission to FDA planned after data analysis.

• Expansion of TG-C indications to hip osteoarthritis (phase 2 approved) and degenerative disc disease (phase 1 approved).

• Continued investment in pipeline expansion, including rheumatoid arthritis and animal health applications.